Pfizer is prioritising its research and development efforts in areas where we can make the biggest difference to health and social care burdens; immunology and inflammation, oncology, cardiovascular and metabolic diseases, neuroscience, pain and vaccines. Through major research efforts across multiple modalities - including small molecules, biologics and vaccines- Pfizer is developing the medical solution that will matter most to the people we serve. Specialised efforts in rare diseases also illustrate our dedication to developing and delivering innovative medicines and vaccines that will benefit patients around the world.
A critical part in the process of bringing new therapies to patients is clinical development- the study of potential new therapies in humans. Pfizer is committed to enhanced clinical and regulatory quality and compliance to build trust among key stakeholders, including patients and payers.
Pfizer has taken a leadership position in creating a discipline around Clinical Innovation, ensuring we are taking advantage of cutting edge tools, approaches and partnerships to ensure our clinical trials are executed with optimal quality, speed and agility. Pfizer's Clinical Innovation investments and initiatives are focused on patient engagement, making work easy for sites to leverage real world data.
Patient safety is a paramount concern for Pfizer, from the moment a new compound is discovered, and for as long as a medicine is prescribed. It is our ethical and regulatory responsibility to monitor the safety of our medicines everywhere they are marketed. Once a drug compound is approved, we continue to monitor its safety and work with governments and others to secure the supply chain and prevent counterfeiting.
We prioritise our R&D efforts in areas with the greatest scientific and commercial promise; immunology and inflammation, oncology, cardiovascular and metabolic diseases, neurosciences and pain, vaccines, rare disease and biosimilars. Through major research efforts across multiple modalities- including small molecules, biologics and vaccines - Pfizer is developing the medical solutions that will matter most to the people we serve.
Transparency is essential to trust and Pfizer has taken a leadership role in the industry concerning the access and sharing of clinical trial results. Recently, we announced a policy that simplifies and broadens access to information gathered in Pfizer sponsored clinical trials. While for several years we have published the results of clinical trials we file with regulators, this expanded policy enables the sharing of anonymous patient- level data from recent Pfizer sponsored studies with qualified investigations outside the company, upon their request. We are also providing, in easy- to-understand language, information on clinical trial results to study participants.
External collaboration is critical to advancing our R&D strategy and expediting new medical breakthroughs. We continue to work with a broad array of organisations to connect the assets and capabilities that have the potential to speed the development of new medicines for patients.